Mieloma Múltiplo: Diagnóstico, Sintomas e Tratamento (Tudo em Um Só Lugar)

Multiple myeloma (MM) is a type of cancer that originates in plasma cells, a type of blood cell that is part of the immune system. Normally, plasma cells produce antibodies to fight infections. In multiple myeloma, these cells become malignant and multiply uncontrollably, accumulating in the bone marrow and producing an abnormal protein called M protein (or paraprotein). Key characteristics of Multiple Myeloma: Plasma cell proliferation: Abnormal plasma cells accumulate in the bone marrow, which can interfere with the production of other normal blood cells (red blood cells, white blood cells, and platelets). Paraprotein production (M protein): The excessive presence of this abnormal protein in the blood can lead to complications such as kidney failure. Bone damage: The proliferation of plasma cells can cause damage to the bones, leading to osteolytic lesions (holes in the bones), osteoporosis, and fractures. Symptoms The symptoms of multiple myeloma can vary, but often include: Bone pain: Especially in the spine and ribs. Bone fractures: Due to weakening of the bones. Anemia: Caused by decreased red blood cell production. Kidney failure: Resulting from the accumulation of abnormal proteins in the kidneys. Fatigue: Due to anemia or metabolic changes. Recurrent infections: Due to immunosuppression. Diagnosis The diagnosis of multiple myeloma is made based on a combination of clinical, laboratory, and imaging findings: Blood tests: Protein electrophoresis: To detect M protein. Immunofixation: To identify the specific type of paraprotein. Complete blood count: To check for anemia. Calcium levels: Elevated due to bone breakdown. Urine tests: Bence Jones protein test: An abnormal protein found in the urine of patients with myeloma. Imaging tests: X-ray, computed tomography (CT) scan, magnetic resonance imaging (MRI), and PET-CT: To identify bone lesions. Bone marrow biopsy: Confirms the presence of malignant plasma cells. Treatment Treatment for multiple myeloma varies depending on the stage of the disease and the patient's overall health, and may include: Chemotherapy: Medications such as bortezomib, lenalidomide, and carfilzomib are commonly used. Corticosteroid therapy: Dexamethasone and prednisone help reduce inflammation and the activity of malignant cells. Bone marrow transplant (hematopoietic stem cell transplant): Autologous transplantation is the most common for patients with MM. Immunotherapy: Includes the use of monoclonal antibodies, such as daratumumab and elotuzumab. Supportive treatment: To control symptoms and complications, such as bisphosphonates to strengthen bones and reduce the risk of fractures. Radiation therapy: Used to treat specific areas of severe bone pain or lesions that do not respond to chemotherapy. Prognosis The prognosis for patients with multiple myeloma has improved significantly in recent decades due to the development of new drugs and treatment strategies. However, it is still considered an incurable disease, but many patients are able to live for many years with good control of symptoms and disease progression.